Search Results
Jul 13, 2026, 07:30 ET Keenova Announces Publication of New Acthar® Gel (repository corticotropin injection) Manuscript in the Journal of Comparative Effectiveness Research
Analysis of physician-reported chartsAuthors: Kyle Hayes, MS; Amit Patel, PhD; Priyanka P. Shanbhag, MS; Destri R. Evans, MBA; Mary Prince Panaccio, PhD; Johanna Purcell, PhD; George J. Wan, PhD, MPHAbout Rheumatoid ArthritisRheumatoid arthritis (RA) is a chronic
More news about: Keenova Therapeutics
Jul 13, 2026, 07:00 ET First-of-its-Kind Surgery Performed on Western Lowland Gorilla at the San Diego Zoo Safari Park
November 2024.Jeffrey Harris, MD, PhD, otolaryngologist-head and neck surgeon, and Kris Suresh, MD, resident fellow at UC San Diego Health, played a critical role in the procedure. While
More news about: San Diego Zoo Wildlife Alliance
Jul 13, 2026, 05:30 ET INDIANA UNIVERSITY AND PHARMATROPHIX PRESENT FINDINGS ON PERFORMANCE OF ORAL THERAPEUTIC, LM11A-31, TO REDUCE DECLINE OF BRAIN FUNCTIONAL-NETWORK CONNECTIVITY IN ALZHEIMER'S DISEASE
disorders that are particularly relevant to cognitive function.The Indiana University research team led by Paul R. Territo, PhD, and Juan Antonio Chong Chie, PhD, processed 18F-FDG-PET scan data from 159 participants in the Phase 2a trial of LM11A-31 with mild to moderate Alzheimer's disease.
More news about: PharmatrophiX
Jul 13, 2026, 04:27 ET ALZpath Demonstrates Global Clinical Impact at AAIC 2026, with Proprietary pTau217 Antibody Anchoring 86 Presentations Demonstrating Clinical and Diagnostic Value Across the Translational Pipeline
Settings presented by Annunziata Di Domenico, PhD (Roche)The Future of Precision Care in Alzheimer's Disease – From Diagnosis Through Management with Blood and Imaging Biomarkers presented by Nicholas Ashton, PhD (Banner Health) & Alireza Atri, MD, PhD (Banner Sun Health Institute) - Sponsored
More news about: ALZpath, Inc.
Jul 13, 2026, 04:00 ET Lighthouse Pharmaceuticals Reports New Evidence that Gingipain Inhibition Benefits Neuropsychiatric Symptoms and Reduces Caregiver Distress in P. gingivalis-Positive Alzheimer's Disease at AAIC 2026
the most challenging aspects of Alzheimer's disease for patients and caregivers, yet no disease modifying treatments exist," said Michael Detke, MD, PhD, Chief Medical Officer of Lighthouse Pharmaceuticals. "These findings suggest that targeting gingipains may provide benefits beyond cognition in Pg-positive
More news about: Lighthouse Pharmaceuticals
Jul 12, 2026, 20:30 ET Deepening Collaboration in AI-Powered R&D Acceleration: Insilico Medicine and CMS announce additional collaborations in CNS diseases
needs.""We are delighted to establish another collaboration with China Medical System just three months after our initial announcement," said Feng Ren, PhD, Co-CEO and Chief Scientific Officer of Insilico Medicine. "Our existing partnership, announced earlier this year, has been seamless and productive
More news about: Insilico Medicine
Jul 12, 2026, 12:00 ET A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
feedback that advances the program toward CTA submission.The planned Phase 1 study will be conducted in collaboration with Roberto Diaz, MD, PhD of The Neuro of McGill University at, along with clinical and scientific experts across McGill-affiliated institutions in Montreal. "When you operate
More news about: HDT Bio Corp.
Jul 10, 2026, 09:24 ET One in Five American Workers Tested Had a Positive Hair Drug Test in 2025, Signaling Persistent Long-Term Substance Use Patterns
resistant to tampering and substitution than traditional methods. This gives employers more accurate insight into safety risks," said Jason S. Hudson, PhD, Scientific Director and Laboratory Director, Workforce Solutions, for Quest Diagnostics. "That matters because substance use in the workplace doesn't
More news about: Quest Diagnostics
Jul 10, 2026, 09:01 ET OpenEvidence Launches EvidenceGrade™, Empowering Physicians To See the Strength of Cited Evidence Beneath Each AI Answer
and when a clinician acts on an answer, it's imperative they understand how much weight the underlying evidence can bear," said Samuel Finlayson, MD, PhD, Senior Vice President of Medical AI at OpenEvidence. "Expert research appraisal teams do invaluable work, but they can't cover every question that comes
More news about: OpenEvidence
Jul 10, 2026, 09:00 ET Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting
Jordi Monés, MD, PhD, to Introduce First Direct-to-Phase 2 Randomized, Controlled Trial of Optogenetic Therapy in Macular DegenerationBenjamin Bakall, MD, PhD, to Present Durable 3-Year REMAIN Follow-Up Data from the RESTORE Phase 2b/3 Trial of MCO-010 in Retinitis
More news about: Nanoscope Therapeutics
Jul 10, 2026, 07:27 ET Breanne J. Kincaid, Ph.D. Joins Bergeson & Campbell, P.C. and The Acta Group as Assistant Toxicologist and Regulatory Scientist
multimedia:https://www.prnewswire.com/news-releases/breanne-j-kincaid-phd-joins-bergeson--campbell-pc-and-the-acta-group-as-assistant-toxicologist-and-regulatory-scientist-302822253.htmlSOURCE
More news about: Bergeson & Campbell, P.C.
Jul 10, 2026, 03:00 ET As Stress, Burnout, and Digital Overload Shape Daily Life, "Doing Nothing" Can Help the Body and Mind Recover
Anupama Kizhakkeveettil, PhD, BAMS, MAOM, L.Ac, FAIHM, C-IAYT, Program Director of Ayurvedic Medicine at SCU, says the idea of doing nothing is often misunderstood."Doing
More news about: Southern California University of Health Sciences
Jul 09, 2026, 16:15 ET /C O R R E C T I O N -- RyboDyn/
"Every therapeutic program begins with a target, and the quality of that target shapes everything that follows," said Corey Dambacher, PhD, Co-founder, President and CTO of RyboDyn and Principal Investigator on the award. "This grant validates our belief that one of the greatest remaining
More news about: RyboDyn
Jul 09, 2026, 16:05 ET Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026
2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties
More news about: Illumina, Inc.
Jul 09, 2026, 13:06 ET GEMMABio Awarded ARPA-H Funding to Pursue Innovative Base-editing Strategy for Rare Liver Diseases
for devastating rare diseases and to distribute these treatments globally," said GEMMABio President and Chief Executive Officer James M. Wilson, MD, PhD. "We believe our work with Profluent will lead to a novel and powerful base-editing approach that can be applied across diverse mutations and genetic
More news about: GEMMA Biotherapeutics
Jul 09, 2026, 11:18 ET The Jackson Laboratory, with the Broad Institute and Partners, Selected for ARPA-H THRIVE Award to Advance Gene Editing Platform for Pediatric Epilepsies and Rare CNS Diseases
something that has to start from scratch and instead build a process that is more systematic, repeatable, and adaptable," said Cathleen (Cat) Lutz, PhD, MBA, vice president and Evnin Family Chair of the Rare Disease Translational Center (RDTC) at The Jackson Laboratory. "AHC and Dravet syndrome are devastating
More news about: The Jackson Laboratory
Jul 09, 2026, 11:15 ET Children's Hospital of Philadelphia Secures Five-year, up to $38.9 Million ARPA‑H Award to Advance Personalized Gene Editing Therapies
Rebecca Ahrens-Nicklas, MD, PhD, Director of CHOP's
More news about: Children's Hospital of Philadelphia
Jul 09, 2026, 08:37 ET ClearCam™ Selected by AFWERX for SBIR Phase I Award to Advance ClearScope IQ™ Surgical Visualization Technology
surgical systems."ClearScope IQ™ is the next evolution of ClearCam™'s approach to enhancing surgical visualization," said Christopher Idelson, PhD, CTO and Co-Founder of ClearCam™, Inc. "With ClearScope IQ™, we are exploring how artificial intelligence can help recognize visualization degradation
More news about: ClearCam Inc.
Jul 09, 2026, 08:30 ET FibroBiologics Appoints Kathleen "Kate" Rubins, Ph.D. to Board of Directors
multimedia:https://www.prnewswire.com/news-releases/fibrobiologics-appoints-kathleen-kate-rubins-phd-to-board-of-directors-302821408.htmlSOURCE
More news about: FibroBiologics, Inc.
Jul 09, 2026, 08:30 ET Spinogenix Appoints Harvard Medical School Professor of Neurology Steven E. Arnold, MD, to Scientific Advisory Board
announced the appointment of Prof. Steven E. Arnold, MD, to its Scientific Advisory Board (SAB). Prof. Arnold serves as the E. Gerald Corrigan PhD Endowed Chair in Alzheimer Therapeutics at Massachusetts General Hospital. He will advise Spinogenix on the continued development of its neuroscience
More news about: Spinogenix
Jul 09, 2026, 08:00 ET National Veterinary Associates Welcomes Laura Tortorella and Tina Hunt, PhD, to Board of Directors
leading pet healthcare services company, today announced the appointment of Laura Tortorella, Chief Executive Officer of AccentCare, and Tina Hunt, PhD, former Executive Vice President of IDEXX Laboratories, to its Board, effective immediately.
More news about: National Veterinary Associates
Jul 09, 2026, 06:11 ET Study Reveals How Lung Tumors "Hack" into Nervous System to Starve the Body
cachexia by essentially hacking into the nervous system and altering eating behavior," said study senior investigator Thales Y. Papagiannakopoulos, PhD, an associate professor in the Department of Pathology at NYU Grossman School of Medicine and a member of Perlmutter Cancer Center. "Many groups have
More news about: NYU Langone Health System
Jul 08, 2026, 20:30 ET Insilico Medicine Releases Positive Profit Alert for the First Half of 2026
non-IFRS net profit in the range of approximately USD45.5 million to approximately USD51.5 million for the First Half of 2026.Alex Zhavoronkov, PhD, Founder, Chairman, Co-CEO and CBO of Insilico Medicine, said: "Since the beginning of 2026, we have achieved a number of collaborations, which have
More news about: Insilico Medicine
Jul 08, 2026, 15:00 ET Health Management Associates Names Arda Ural Chief Operating Officer
unique mission to improve lives by helping our clients make health and human services more accessible, effective, and sustainable," said Arda Ural, PhD.Prior to joining HMA, Ural was the Americas Life Sciences leader at EY, accountable for strategy, consulting, M&A, technology, tax, and assurance
More news about: Health Management Associates
Jul 08, 2026, 13:23 ET American Tinnitus Association Establishes ATA Academy to Close Critical Gap in Tinnitus Provider Education
dynamic, evidence-based approaches. Course materials will become available in early 2027.Led by Dr. Hannah GlickDr. Hannah Glick, AuD, PhD, CCC-A, will lead ATA Academy. Dr. Glick joined ATA in May 2026 as vice president of Tinnitus Programming. She is dually trained as an audiologist and
More news about: American Tinnitus Association